Medical Device Market Access: What Value Analysis Committees Really Want and How to Build Your Go-to-Market Strategy

2026-09-23 · Caduvo Team

Medical device market access depends on convincing hospital value analysis committees with clinical and economic evidence. Learn how VACs evaluate new technologies and how to sequence a go-to-market strategy that actually works.

Most MedTech founders think market access begins with a payer coverage decision. They’re wrong. For devices used in hospitals, the first — and often hardest — gatekeeper is the Value Analysis Committee. Get past the VAC and you might never need to argue with a national payer. Fail to convince them and you won’t sell a single unit, no matter how many codes you have.

Medical device market access is not a single milestone. It is the sequence of decisions that determine whether a product reaches patients, gets used, and — critically — gets paid for. That sequence runs through regulatory clearance, coding, coverage, and contracting. But inside hospitals, it also runs through a committee most teams underestimate.

What Medical Device Market Access Actually Means

For medical devices, market access refers to the full path from FDA authorization to a clinician’s hand. It includes:

• A clear regulatory classification and clearance or approval.
• A payment pathway — usually an HCPCS or CPT code — that lets the facility or clinician bill for the procedure.
• Payer coverage policies, whether via national coverage determinations or local MAC LCDs.
• Hospital-level approval, where Value Analysis Committees decide whether to add the device to the formulary or approved product list.

Many first-time commercial leaders conflate coding with market access. A new HCPCS code is necessary but insufficient. The code opens the door to payment; the VAC decides if the door stays open.

Inside the Value Analysis Committee

A Value Analysis Committee is a cross-functional hospital team that reviews new product requests. The committee evaluates whether a technology improves clinical outcomes, reduces cost, or both — always measured against the status quo.

Members typically include:

• Supply chain and materials management
• Nursing leadership
• Physician champions from relevant service lines
• Infection prevention (for many device categories)
• Finance or revenue integrity
• Administration

VACs meet monthly or quarterly. A single negative vote can delay or kill a request for a year. They are not subtle. They expect data, not relationships.

For a deeper breakdown of VAC dynamics and evidence categories, see our full guide.

The Evidence Package VACs Expect

When you submit a product for review, the committee wants two things: a clinical case and a financial case. Both must be specific to the hospital’s patient population and reimbursement structure.

Clinical evidence must answer:

• Does the device reduce length of stay, complications, readmissions, or revision surgeries?
• Is there peer-reviewed data from a comparable setting?
• What is the learning curve and how does it affect outcomes?

Case studies and white papers don’t count. VACs want published, comparative data — ideally a randomized trial, but at minimum a well-matched observational study against the current standard device or technique.

Economic evidence must show:

• Procedure-level cost comparison, including device price, OR time, and associated disposables.
• Episode-of-care impact: 30-day or 90-day cost, DRG margin, or cost per quality-adjusted life year if relevant.
• Reimbursement mapping: which HCPCS or CPT code(s) capture the procedure, and what is the average payment under the hospital’s payer mix.

A common mistake is presenting list-price savings alone. The committee cares about net cost to the hospital after reimbursement. If your device adds $800 in cost but reduces length of stay by 0.8 days on a surgical MS-DRG, you must show that arithmetic clearly.

Building a Realistic Go-to-Market Sequence

For a first product, the temptation is to chase wide coverage on day one. That sequence almost never works. A more reliable medical device go to market strategy phases adoption geographically and by site type.

Phase 1: Anchor accounts (3–5 hospitals). Target sites where you already have a physician champion and where the reimbursement pathway is established. Generate real-world utilization data, cost analyses, and patient-reported outcomes. These are your evidence factories. During this phase, you do not need a distinct HCPCS code if an existing category code fits — but you must confirm that the code is accepted by the local MAC and the hospital’s chargemaster.

Phase 2: Regional expansion with payer engagement. With anchor data, approach commercial payers in the same geography. Offer a risk-sharing or warranty arrangement if possible. At the same time, pursue any necessary coding updates (a new application for a HCPCS code if the device doesn’t fit an existing descriptor). Monitor Medicare coverage databases for LCD drafts that might affect your technology.

Phase 3: National scaling. Only after you have 12–18 months of published data, regional payer contracts, and a refined VAC evidence package should you push for national commercial coverage and broader hospital adoption. By this point, the VAC conversation at new accounts becomes: “Here’s the data from five peer institutions; here’s the average cost reduction; here’s the reimbursement support.”

The key is to sequence your evidence generation ahead of your expansion, not parallel to it. Every new VAC you approach should see stronger data than the last.

Actionable Takeaways

• Treat the Value Analysis Committee as the central hurdle in medical device market access — not an afterthought after coding.
• Build an evidence package that answers two questions for the hospital: “Will this improve clinical outcomes?” and “What is the net financial impact after reimbursement?”
• Use anchor accounts to generate comparative data before chasing broad coverage. A handful of strong VAC wins beat a thousand cold submissions.
• Map your reimbursement pathway early. If your device doesn’t fit an existing HCPCS code, start the application process during Phase 1, not after FDA clearance.
• Prepare a one-page VAC summary that shows procedure cost, code, average payment, and key clinical endpoints. If you can’t fit it on a page, you haven’t simplified enough.